2026-08-04First statedFinancial results presentation
「In addition to the impact of continuing drug price revisions in the prescription pharmaceutical business, revenue declined due to difficulties procuring active pharmaceutical ingredients for core products in the overseas business amid the worsening situation in the Middle East.
Profit was affected by higher cost of sales resulting from increased raw-material prices and other factors, as well as higher research and development expenses associated with clinical trial progress. Operating profit fell 51.4% year on year, ordinary profit fell 48.7%, and net profit attributable to owners of the parent fell 57.5%.」
In the first quarter of the fiscal year ending March 2027, revenue was ¥17,384 million, down 1.5% year on year, and operating profit was ¥711 million, down 51.4%.